When Pronova BioPharma needed a facilities upgrade with minimum downtime, the company called on NNE Pharmaplan. The result was a GMP-compliant production plant with doubled capacity and fast-tracked resumption of production.
Pronova BioPharma is a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products. The company’s lead product is manufactured at its plant in Norway using a complex proprietary process.
Having experienced strong growth over the past three years, with demand increasing for its active pharmaceutical ingredient (API), the company decided to open a second manufacturing site in Denmark.
Meeting increasing demand with minimum downtime
The project needed to be approached as a “pit stop” project – with a short shutdown period and a fast-tracked resumption of updated production when the shutdown was over.
NNE Pharmaplan provided a complete range of services, from conceptual design to construction management and qualification. This also included a new distillation unit, a DeltaV automation upgrade on the existing distillation unit, a GMP upgrade on parts of the units and much more.
The results have been a doubling of production capacity with minimum of down periods. Pronova BioPharma can now continue to meet demand for its innovative pharmaceutical ingredients.